

## TotalSeq™-A0014 anti-mouse/human CD11b Antibody

<b>Catalog# / Size</b>	101265 / 10 µg
<b>Clone</b>	M1/70
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	αM integrin, Mac-1, Mo1, CR3, Ly-40, C3biR, ITGAM
<b>Isotype</b>	Rat IgG2b, κ
<b>Barcode Sequence</b>	TGAAGGCTCATTGT
<b>Description</b>	CD11b is a 170 kD glycoprotein also known as αM integrin, Mac-1 α subunit, Mol, CR3, and Ly-40. CD11b is a member of the integrin family, primarily expressed on granulocytes, monocytes/macrophages, dendritic cells, NK cells, and subsets of T and B cells. CD11b non-covalently associates with CD18 (β2 integrin) to form Mac-1. Mac-1 plays an important role in cell-cell interaction by binding its ligands ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, and fibrinogen.

### Product Details

<b>Verified Reactivity</b>	Mouse, Human, Cynomolgus, Rhesus
<b>Reported Reactivity</b>	Chimpanzee, Baboon, Rabbit
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	C57BL/10 splenocytes
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 1 mM EDTA.
<b>Preparation</b>	The antibody was purified by chromatography and conjugated with TotalSeq™-A oligomer under optimal conditions.
<b>Concentration</b>	0.5 mg/ml
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">PG - Quality tested</a>
<b>Recommended Usage</b>	<p>Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> and the oligomer sequence is confirmed by sequencing. TotalSeq™-A antibodies are compatible with 10x Genomics Single Cell Gene Expression <a href="#">Solutions</a>.</p> <p>To maximize performance, it is strongly recommended that the reagent be titrated for each application, and that you centrifuge the antibody dilution before adding to the cells at 14,000xg at 2 - 8°C for 10 minutes. Carefully pipette out the liquid avoiding the bottom of the tube and add to the cell suspension. For Proteogenomics analysis, the suggested starting amount of this reagent for titration is ≤ 1.0 µg per million cells in 100 µL volume. Refer to the corresponding TotalSeq™ protocol for specific staining instructions.</p> <p>Buyer is solely responsible for determining whether Buyer has all intellectual property rights that are necessary for Buyer's intended uses of the BioLegend TotalSeq™ products. For example, for any technology platform Buyer uses with TotalSeq™, it is Buyer's sole responsibility to determine whether it has all necessary third party intellectual property rights to use that platform and TotalSeq™ with that platform.</p>
<b>Application Notes</b>	<p>Clone M1/70 has been verified for immunocytochemistry (ICC) and frozen immunohistochemistry (IHC-F).</p> <p>Additional reported applications (for relevant formats of this clone) include: immunoprecipitation<sup>1,4</sup>, <i>in vitro</i> blocking<sup>3,9,12</sup>, depletion<sup>2,8</sup>, immunofluorescence microscopy<sup>6,7,10</sup>, immunohistochemistry of acetone-fixed frozen sections<sup>5,11-13</sup>, and spatial biology (IBEX)<sup>35,36</sup>. For <i>in vivo</i> studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Endotoxin &lt; 0.01 EU/µg, Azide-</p>

Free, 0.2 µm filtered) (Cat. No. 101248).

#### Additional Product Notes

TotalSeq™ reagents are designed to profile protein levels at a single cell level following an optimized protocol similar to the CITE-seq workflow. A compatible single cell device (e.g. [10x Genomics Chromium System and Reagents](#)) and sequencer (e.g. Illumina analyzers) are required. Please contact [technical support](#) for more information, or visit [biolegend.com/totalseq](#).

The barcode flanking sequences are CCTTGGCACCCGAGAATTCCA (PCR handle), and BAAAAAAAAAAAAAAAAAAAAAAAAAAAAA\*A\*A (capture sequence). B represents either C, G, or T, and \* indicates a phosphorothioated bond, to prevent nuclease degradation.

View more applications data for this product in our [Scientific Poster Library](#).

#### Application References

(PubMed link indicates BioLegend citation)

1. Springer T, *et al.* 1978. *Eur. J. Immunol.* 8:539. (IP)
2. Ault K and Springer T. 1981. *J. Immunol.* 126:359. (Deplete)
3. Springer TA, *et al.* 1982. *Immunol. Rev.* 68:171. (Block)
4. Ho MK and Springer TA. 1983. *J. Biol. Chem.* 258:2766. (IP)
5. Flotte TJ, *et al.* 1983. *Am. J. Pathol.* 111:112. (IHC)
6. Noel GJ, *et al.* 1990. *J. Clin. Invest.* 85:208. (IF)
7. Allen LA and Aderem A. 1996. *J. Exp. Med.* 184:627 (IF)
8. D'Amico A and Wu L. 2003. *J. Exp. Med.* 198:293. (Deplete)
9. Brickson SJ, *et al.* 2003. *Appl Physiol.* 95:969. (Block)
10. Clatworthy MR and Smith KG. 2004. *J. Exp. Med.* 199:717. (IF)
11. Hata H, *et al.* 2004. *J. Clin. Invest.* 114:582. (IHC)
12. Zhang Y, *et al.* 2002. *J. Immunol.* 168:3088. (IHC)
13. Iwasaki A and Kelsall BL. 2001. *J. Immunol.* 166:4884 (IHC, FC)
14. Tailleux L. 2003. *J. Exp. Med.* 197:121. (Block, FC)
15. Olver S, *et al.* 2006. *Cancer Research* 66:571. (FC)
16. Tan SL, *et al.* 2006. *J. Immunol.* 176:2872. (FC) [PubMed](#)
17. Ponomarev ED, *et al.* 2006. *J. Immunol.* 176:1402. (FC)
18. Dzhagalov I, *et al.* 2007. *Blood* 109:1620. (FC)
19. Fazilleau N, *et al.* 2007. *Nature Immunol.* 8:753.
20. Rasmussen JW, *et al.* 2006. *Infect. Immun.* 74:6590. [PubMed](#)
21. Napimoga MH, *et al.* 2008. *J. Immunol.* 180:609. [PubMed](#)
22. Elqaraz-Carmon V, *et al.* 2008. *J. Lipid. Res.* 49:1894. [PubMed](#)
23. Kim DD, *et al.* 2008. *Blood* 112:1109. [PubMed](#)
24. Guo Y, *et al.* 2008. *Blood* 112:480. [PubMed](#)
25. Norian LA, *et al.* 2009. *Cancer Res.* 69:3086. (FC) [PubMed](#)
26. Baumgartner CK, *et al.* 2010. *J. Immunol.* 184:573. [PubMed](#)
27. Charles N, *et al.* 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
28. Whiteland J, *et al.* 1995. *J. Histochem. Cytochem.* 43:313. (IHC)
29. Weber GF, *et al.* 2014. *J Exp Med.* 211:1243. [PubMed](#)
30. Ashok A, *et al.* 2015. *Toxicol Sci.* 143:64. [PubMed](#)
31. Price PJ, *et al.* 2015. *J Immunol.* 194:1164. [PubMed](#)
32. Doni A, *et al.* 2015. *J Exp Med.* 212:905. [PubMed](#)
33. Ferreira R, *et al.* 2016. *J Infect Dis.* 213: 669 - 673. [PubMed](#)
34. Peterson VM, *et al.* 2017. *Nat. Biotechnol.* 35:936. (PG)
35. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
36. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

#### Product Citations

1. Rødahl I, *et al.* 2021. *STAR Protoc.* 2:100842. [PubMed](#)
2. Golomb SM, *et al.* 2020. *Cell Rep.* 33:108438. [PubMed](#)
3. Guldner IH, *et al.* 2020. *Cell.* 183(5):1234-1248.e25. [PubMed](#)
4. Guilliams M, *et al.* 2022. *Cell.* 185:379. [PubMed](#)
5. Wirka RC, *et al.* 2019. *Nat Med.* 25:1280. [PubMed](#)
6. Guldner IH, *et al.* 2021. *STAR Protocols.* 2(2):100537. [PubMed](#)
7. Hao Y, *et al.* 2021. *Cell.* 184:3573. [PubMed](#)
8. Pisu D, *et al.* 2021. *J Exp Med.* 218:. [PubMed](#)

#### RRID

AB\_2734152 (BioLegend Cat. No. 101265)

## Antigen Details

---

<b>Structure</b>	Integrin family, associates with integrin β <sub>2</sub> (CD18), 170 kD
<b>Distribution</b>	Granulocytes, monocytes/macrophages, dendritic cells, NK cells, subsets of T and B cells
<b>Function</b>	Adhesion, chemotaxis
<b>Ligand/Receptor</b>	ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, fibrinogen
<b>Cell Type</b>	B cells, Dendritic cells, Granulocytes, Macrophages, Monocytes, Neutrophils, NK cells, T cells, Tregs
<b>Biology Area</b>	Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity,

Neuroscience, Neuroscience Cell Markers

**Molecular Family**

Adhesion Molecules, CD Molecules

**Antigen References**

1. Barclay A, *et al.* 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Springer TA. 1994. *Cell* 76:301.
3. Coxon A, *et al.* 1996. *Immunity* 5:653.

**Gene ID**

[16409](#)

[3684](#)

---

**Related Protocols**

[TotalSeq™-A Antibodies and Cell Hashing with 10x Single Cell 3' Reagent Kit v3 3.1 Protocol](#)

---

**Other Formats**

APC anti-mouse/human CD11b, Biotin anti-mouse/human CD11b, FITC anti-mouse/human CD11b, PE anti-mouse/human CD11b, PE/Cyanine5 anti-mouse/human CD11b, Purified anti-mouse/human CD11b, PE/Cyanine7 anti-mouse/human CD11b, Alexa Fluor® 488 anti-mouse/human CD11b, Alexa Fluor® 647 anti-mouse/human CD11b, Alexa Fluor® 700 anti-mouse/human CD11b, Pacific Blue™ anti-mouse/human CD11b, APC/Cyanine7 anti-mouse/human CD11b, PerCP/Cyanine5.5 anti-mouse/human CD11b, PerCP anti-mouse/human CD11b, Brilliant Violet 421™ anti-mouse/human CD11b, Brilliant Violet 570™ anti-mouse/human CD11b, Brilliant Violet 605™ anti-mouse/human CD11b, Brilliant Violet 650™ anti-mouse/human CD11b, Brilliant Violet 711™ anti-mouse/human CD11b, Brilliant Violet 785™ anti-mouse/human CD11b, Brilliant Violet 510™ anti-mouse/human CD11b, Ultra-LEAF™ Purified anti-mouse/human CD11b, Purified anti-mouse/human CD11b (Maxpar® Ready), Alexa Fluor® 594 anti-mouse/human CD11b, PE/Dazzle™ 594 anti-mouse/human CD11b, APC/Fire™ 750 anti-mouse/human CD11b, TotalSeq™-A0014 anti-mouse/human CD11b, Brilliant Violet 750™ anti-mouse/human CD11b, TotalSeq™-B0014 anti-mouse/human CD11b, TotalSeq™-C0014 anti-mouse/human CD11b, Spark NIR™ 685 anti-mouse/human CD11b, PE/Fire™ 640 anti-mouse/human CD11b, Spark YG™ 593 anti-mouse/human CD11b, Spark YG™ 570 anti-mouse/human CD11b, PE/Fire™ 810 anti-mouse/human CD11b, APC/Fire™ 810 anti-mouse/human CD11b Antibody, Spark Blue™ 550 anti-mouse/human CD11b, Spark UV™ 387 anti-mouse/human CD11b

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587